BEAM vs LEN · rev $63.5M vs rev $34.19B
Beam Therapeutics Inc (BEAM) versus LEN (LEN) — a side-by-side from cached financials, not a winner call.
Beam Therapeutics Inc (BEAM) is a biotechnology company listed on US.
LEN (LEN) common stock.
Latest reported BEAM revenue for 2024-12-31 was $63.5M. Net income was -$376.7M. Revenue was down 83.2% from 2023-12-31 to 2024-12-31. BEAM currently screens at market cap $2.01B.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
BEAM currently screens at market cap $2.01B. LEN currently screens at market cap $0.
Not investment advice. Open the BEAM and LEN stock pages for the full models.
Not investment advice.